Open AccessKetanserin and Red Blood Cell Sodium Content in Hypertension
Author(s) -
J. De Crée,
J. Leempoels,
B Demoen,
H. Verhaegen
Publication year - 1985
Publication title -
journal of cardiovascular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/00005344-198500077-00013
Subject(s) - ketanserin , endocrinology , sodium , red blood cell , serotonergic , medicine , chemistry , serotonin , ouabain , essential hypertension , pharmacology , placebo , antagonist , receptor , blood pressure , 5 ht receptor , pathology , alternative medicine , organic chemistry
The sodium content of erythrocytes from patients with essential hypertension is increased. In a double-blind, placebo-controlled study, a 5-day treatment with ketanserin, a serotonergic antagonist lowered significantly the sodium content of the red blood cells (RBC). Ouabain induces an increase of sodium content of the RBC, which is paralleled by a decrease in RBC deformability. The ouabain-dependent fraction of RBC deformability is significantly reduced after a single oral dose of ketanserin. In vitro, serotonin (5-HT) decreases RBC deformability; this effect could be antagonized by ketanserin. These data might suggest a regulating role of 5-HT in transmembrane ion fluxes.